---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-003158"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:15:44.622610+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma appoints Kirsten Flowers to Board; Dr. Peter Thompson resigns

## Summary
- Dr. Peter Thompson resigned from the board and committees effective January 5, 2022; not related to any disagreement.
- Kirsten Flowers appointed Class I director effective January 5, 2022, filling the vacancy until the 2024 annual meeting.
- Ms. Flowers is Chief Commercial Officer of Kura Oncology, with prior roles at Array Biopharma and Pfizer.
- Her compensation follows the Company's Outside Director Compensation Policy; an indemnification agreement was executed.
- No arrangements or family relationships exist between Ms. Flowers and any other director or officer.

## SEC filing metadata
- accession: 0001193125-22-003158
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/d86525d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-003158
- JSON: https://secwatch.observer/filing/0001193125-22-003158.json
- Plain text: https://secwatch.observer/filing/0001193125-22-003158.txt

## Key facts
- Executive change
  Peter Thompson resigned as Director at PMV Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 5, 2022, Peter Thompson, M.D. notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effected on January 5, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm
- Executive change
  Kirsten Flowers was appointed as Director at PMV Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 5, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Kirsten Flowers as a director and Class I director of the Company to fill the vacancy of Dr. Thompson’s seat on the Board of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.